Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Legend Biotech CorporationNASDAQ: LEGN

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation turns negative

Q3 FY2026 stock-based compensation was -$9.6M, compared with $15.02M a year earlier. Trailing-twelve-month stock-based compensation was $7.7M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 11.0 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near -$9.6M or moves back toward the trailing-twelve-month quarterly average of $1.93M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$9.6M-155.5% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$7.7M-87.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-163.9%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 stock-based compensation of $7.7M is the 8th largest of the 11 companies compared; the peer median is $10.8M.
  • Its year-over-year change of -87.8% is the lowest of 11, against a peer median of -34.0%.
  • Stock-based compensation amounts to 0.6% of revenue for LEGN, versus a peer median of 63.4%.
LEGN Competitors Peer median
Stock-Based Compensation for LEGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M +19.3%—115500.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M -35.1%-23.4%—
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M -43.3%-31.8%340.0%
AUTLAutolus Therapeutics plcLTM Mar 2026$15.14M -5.7%+6.3%16.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M +36.3%-2.0%587.9%
DTILPrecision BioSciences, Inc.LTM Mar 2026$8.91M -28.8%-19.0%19.8%
LEGNLegend Biotech CorporationLTM Sep 2026$7.7M -87.8%—0.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$6.29M -72.4%-43.4%27.2%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$5.86M -50.8%-13.8%—
CLLSCellectis S.A.LTM Mar 2026$1.28M -60.6%—1.9%
Peer median (excluding LEGN) $10.8M-34.0%-16.4%63.4%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(407.2M)(445.72M)(520.12M)(158.13M)(297.58M)
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
Deferred Income Tax00000
Stock-Based Compensation20.16M34.34M47.68M68.94M0
Change in Working Capital161.83M181.03M(71.34M)20.04M(93.35M)
Accounts Receivables24.59M50.32M(98.98M)93.75M(132.85M)
Inventory51K(13.89M)(12.71M)(17.21M)(4.51M)
Accounts Payables1.81M72.45M(50.2M)14.06M44.52M
Other Working Capital135.39M72.16M90.54M(70.57M)(501.32K)
Other Non-Cash Items12.82M10.68M130.06M(98.24M)261.57M
Operating Cash Flow(198.47M)(201.28M)(393.28M)(144.03M)(100.47M)
Capital Expenditures(45.4M)(22.28M)(22.72M)(14.11M)(67.58M)
Acquisitions (Net)00000
Purchases of Investments(377.96M)(654.97M)(4.86B)(2.71B)(4.55B)
Sales of Investments230.08M614.86M5.08B1.93B5.33B
Other Investing Activities(4.91M)(16.05M)(100.52M)(54.34M)0
Investing Cash Flow(194.98M)(77.09M)92.79M(850.54M)711.48M
Debt Repayment(1.42M)(2.6M)(3.76M)(4.02M)0
Common Stock Issued623.44M377.64M003.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.64M2.93M795.25M9.72M(3.61M)
Financing Cash Flow626.66M377.98M791.49M5.7M(300.79K)
Effect of Forex Changes34K(2.51M)682K(2.09M)4.37M
Net Change in Cash233.25M97.09M491.68M(990.96M)615.09M
Free Cash Flow(243.87M)(223.56M)(416M)(158.14M)(168.04M)

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.